ISG Provider Lens™ Specialty Analytics Services - Life Sciences and Healthcare - Life Sciences and Healthcare - Global 2025

From lagging reports to achieving real-time decision augmentation, AI is improving healthcare outcomes

The advances in data, analytics, Generative AI (GenAI) and agentic AI are transforming how healthcare and life sciences (HCLS) organizations deliver care, accelerate research, manage operations and engage patients. These innovations are driving measurable improvements in efficiency, accuracy and patient outcomes; however, adoption is not without challenges. Regulatory complexity, talent shortages, operational pressures and the need for responsible AI use demand thoughtful strategies. Organizations that can simultaneously innovate, scale responsibly and work closely with analytics partners to translate analytics goals into tangible outcomes will be the ones to succeed.

The shift from descriptive reporting to predictive and adaptive analytics is underway across life sciences, providers and payers.

What was once limited to experimentation, is increasingly becoming mission critical. However, the way these capabilities appear across the three verticals reflects their unique operational realities and pressures.

Transformation across the value chain

Life sciences organizations are applying analytics far beyond drug commercialization. Drug discovery and development processes are being accelerated through AI-enabled trial simulations and the integration of realworld data (RWD) and real-world evidence (RWE). Decentralized clinical trial models are supported by wearable device data, creating richer datasets, while improving participant access and reducing adverse events. Beyond trials, commercial and operational functions are adopting analytics to improve launch planning, patient adherence, healthcare provider engagement and field sales effectiveness. Omnichannel marketing campaigns are being powered by AI to identify the right channels,
timing and messaging for each stakeholder. Manufacturing facilities and supply chains are evolving into connected ecosystems with a combination of analytics, blockchain and IoT for end-to-end visibility and control. These applications reduce time to market and increase the likelihood of therapy adoption and long-term adherence, reinforcing business performance and patient trust.

On the healthcare provider side, analytics and AI are addressing systemic workforce shortages and financial strain. Hospitals and healthcare systems are deploying predictive tools for patient throughput, hospital stay management and readmission prevention. These analyticsdriven insights help allocate staff and resources more effectively, easing operational bottlenecks. Clinical decision support systems, now enhanced by GenAI, provide concise evidence-based summaries of complex patient histories, augmenting physicians’ decisions on care management. Intelligent virtual
assistants and chatbots are transforming patient engagement, helping organizations triage demand while enhancing experience. Providers are also using AI-driven performance management dashboards to monitor physician productivity, improve utilization and identify opportunities for quick wins, such as reducing documentation backlogs or optimizing resource scheduling. These applications ensure financial resilience without compromising care quality and operations.

Meanwhile, for healthcare payers, the early focus on actuarial modeling has evolved into enterprisewide adoption of advanced analytics. Fraud detection, contract intelligence and anomaly detection are helping insurers reduce leakage and streamline adjudication. Predictive disease models are supporting proactive member outreach, reducing avoidable
costs while improving healthcare outcomes. Member engagement is being redefined through digital assistants and personalized touchpoints that anticipate member needs instead of simply reacting and managing population healthcare at large. Case managers are beginning to rely on agentic AI copilots that provide real-time  recommendations during patient interactions, reducing cognitive load and improving care coordination. These capabilities contain costs and also reinforce trust among regulators, providers and members, which is a critical  differentiator in an increasingly competitive market.

At the heart of this transformation are GenAI and agentic AI, which add entirely new dimensions to what analytics can achieve. GenAI enables regulatory-ready documentation, automated summarization of electronic health records (EHRs) and the generation of contextual, user-friendly communications. For researchers, it accelerates literature reviews and supports hypothesis generation, compressing weeks of work into hours. For clinicians, it offers instant chart summaries and draft documentation, allowing them to focus more on patients than on paperwork. Agentic AI goes further by acting autonomously in bounded workflows, automating prior authorizations, issuing hospital  admission alerts or assisting case managers during member interactions. Together, they mark a shift from static models to adaptive, self-learning systems capable of continuous improvement in real time. For organizations under relentless cost and performance pressures, these innovations are more than promising; they are rapidly becoming essential.

Yet, realizing this potential requires more than technology adoption. Most enterprises face challenges with fragmented data, legacy systems and a shortage of skilled professionals who can interpret complex outputs in clinical, operational or regulatory contexts. The ability to translate insights into actions remains inconsistent across the industry. This is where specialist providers play a critical role, bridging the gap between goals and execution.

The role of specialist providers

Specialist providers bring domain expertise and technology prowess that unify data, analytics and AI capabilities into modular, interoperable architectures. These platforms often include:

• Data pipelines and engineering accelerators for ingesting, cleaning and normalizing diverse datasets across clinical, claims, genomic and patient-reported sources

• MLOps and LLMOps frameworks for ongoing monitoring, governance and retraining of models to maintain  transparency and avoid any bias

• Domain-specific AI models and GenAI prompts tailored to payer, provider and life sciences use cases

• Agentic AI copilots and automation workflows embedded into day-to-day operations, from clinical documentation to
utilization management

• Cloud-native scalability through partnerships with AWS, Azure, Snowflake and Databricks, ensuring resilience and compliance at scale

Crucially, these providers also bring regulatory acumen, ensuring that the Health Insurance Portability and  Accountability Act (HIPAA), Food and Drug Administration (FDA), GDPR and other compliance standards are integrated into every solution. They help organizations adopt technology and also sustain it responsibly in sensitive, high-stakes
environments. Their engagement models allow clients to scale adoption gradually, avoiding high upfront investments, while still achieving near-term wins. This combination of technical capability, domain expertise and regulatory alignment makes them vital partners in turning analytics strategies into measurable business and patient outcomes.

Across the HCLS landscape, the strategic imperative is becoming clear; analytics, GenAI and agentic AI are no longer just peripheral enablers. They are the foundation for competitive resilience and long-term relevance. For payers, they mean sharper actuarial insights and more personalized member engagement. For providers, they mean financial stabilization and improved patient experience amid workforce constraints. For life sciences, they enable faster trials, smarter launches and stronger patient adherence. For all, they offer the ability to adapt in real time to regulatory shifts, operational setbacks and market volatility.

The organizations that move decisively, balancing innovation with compliance and leveraging trusted providers for scale, will unlock new levels of efficiency, agility and patient trust. The ones that delay, constrained by legacy thinking or piecemeal approaches, risk being left behind in an industry where speed and intelligence are becoming defining currencies.

For HCLS CXOs, it should be less about selecting the most suitable technology and more about aligning with a partner whose priorities and incentives are tied to long-term business outcomes. Achieving this alignment requires clarity of vision, openness to shared accountability and a willingness to trust partners to cocreate solutions rather than controlling every decision internally. By treating analytics providers as extensions of their enterprise, rather than merely service vendors, CXOs can foster relationships that drive sustained value, adaptability and innovation at scale.

Access to the full report requires a subscription to ISG Research. Please contact us for subscription inquiries.